Bayer's Finerenone Stacks Up More CV Benefit Data Ahead Of Potential Approval

 
• By Jessica Merrill

The FIGARO-DKD cardiovascular outcomes trial showed finerenone reduced composite risk of CV death or non-fatal events in CKD patients with Type 2 diabetes, including earlier-stage patients.

Heart health
Bayer's finerenone showed a significant benefit in a CV outcomes trial • Source: Alamy

More from Genitourinary

More from Therapy Areas